Drug Trial Radar · NCT07127770
A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Aug 28, 2025
Primary completion
Oct 8, 2025
Study completion Nov 7, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn how the body processes the study medicine PF-07104091. The study is seeking participants who are: \- Healthy male aged 18 to 65 years of age Participants in the study will receive 14C-labeled PF-07104091 by mouth after a meal. After 14 days, the participants will receive PF-07104091 by mouth (after a meal) followed by IV fusion (given directly into a vein) of microdose \[14C\]PF-07104091. The study will help understand how the body processes study medicine PF-07104091 and how the medicine is changed and removed from the body after you take it. This study will also help to understand how much PF-07104901 is taken up into the blood. Participants will remain in the study clinic for a maximum of 23 days and will have one follow-up contact.
Conditions
- Healthy Adults
Interventions
PF-07104091Drug
Cyclin-dependent kinase-2 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Total Radiocarbon (14c) excreted in urineTime frame: From Predose up to 14 days post dose of period 1 and 2
- Percentage of Total Radiocarbon (14c) excreted in fecesTime frame: From Predose up to 14 days post dose of period 1 (and if applicable for Period 2)
- Percentage of Total Radiocarbon (14c) excreted in vomitus (if applicable)Time frame: From Predose up to 14 days post dose of period 1 only
- Cumulative Percent Recovery of Total Radiocarbon (14C)Time frame: From Predose up to 14 days post dose of period 1 only
- Percentage of Metabolite Detected in Plasma After Oral Administration of PF-07104091Time frame: From Predose to 14 days post dose of period 1
- Percentage of Metabolite Detected in Urine After Oral Administration of PF-07104091Time frame: From Predose to 14 days post dose of period 1
- Percentage of Metabolite Detected in Feces After Oral Administration of PF-07104091Time frame: From Predose to 14 days post dose of period 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON
Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.